Diane Gosselin
Chief Executive Officer @ CQDM
Montréal, Canada
Diane Gosselin is a seed investor at CQDM in Montréal focused on Biotechnology and Chemical. Diane Gosselin is the Chief Executive Officer at CQDM. Diane attended the College of Corporate Directors / Laval University.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Diane Gosselin invests in
Stages Diane Gosselin invests in
Countries Diane Gosselin invests in
Investment Focus
Industry
- Biotechnology 2 (100%)
- Chemical 1 (50%)
- Biopharma 1 (50%)
- Health Care 1 (50%)
- Life Science 1 (50%)
Stage
- Seed 1 (50%)
- Funding Round 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Giiant Pharma
|
Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerabilityand enhanced therapeutic effect. | $12.4M / Seed / May 21, 2021 | |
Encycle Therapeutics
|
Encycle Therapeutics is a Toronto-based biotech company exploiting a unique platform technology that enables the rapid synthesis of drug-like macrocycles or membrane-permeable nacellins. Nacellins have enormous potential to target intracellular protein-protein interactions, which are largely intractable to small molecule and biologic modulation,and can represent cheaper, oral equivalents to existing biologics (e.g., monoclonal antibodies). Encycle has collaborated with several pharmaceutical companies to complete a screening library of nacellins, many of which are cell-permeable and possess other drug-like properties. The company is also pursuing independent development of nacellins against integrin alpha-4-beta-7 (IBD) and SMURF2 (fibrosis); its lead program seeks to develop orally bioavailable inhibitors of integrin alpha-4-beta-7, which are safer and less immunogenic than marketed and investigational biologics targeting the same protein. | $840K / Jun 16, 2015 |
Co-Investors
About CQDM
CQDM is a drug discovery company that brings together researchers in academia, biotechs and the pharma industry.
CQDM Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Diane Gosselin
Chief Executive Officer
|
|||
Jesse Paterson
Senior Director, Business Development
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Diane Gosselin invest in?
Diane Gosselin invests primarily in Biotechnology, Chemical and Biopharma startups, most often at Seed and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Diane Gosselin last invest?
The most recent investment recorded for Diane Gosselin closed in May 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
